Inhaled high-dose beclomethasone in chronic asthma.

Area of Science:

• Pulmonology
• Allergy and Immunology
• Pharmacology

Background:

• Asthma patients often require oral corticosteroids for control.
• Standard inhaled corticosteroid doses may be insufficient for some patients.
• High-dose inhaled beclomethasone dipropionate (BDP) offers a potential alternative.

Purpose of the Study:

• To evaluate the efficacy of high-dose inhaled beclomethasone dipropionate (250 micrograms/metered dose) in inadequately controlled asthma patients.
• To assess the impact on oral corticosteroid dependence and asthma exacerbations.

Main Methods:

• Retrospective study of 123 asthma patients.
• Patients received high-dose inhaled beclomethasone dipropionate (BDP) 250.
• Data analyzed for changes in oral steroid dosage, asthma control, and exacerbation rates.

Main Results:

• 69% of patients showed improved asthma control.
• 31% of steroid-dependent patients discontinued oral steroids; 48% reduced dosage.
• Significant reductions in acute attacks (53%) and hospital admissions (70%) were observed.

Conclusions:

• High-dose inhaled beclomethasone dipropionate (BDP) 250 is effective in improving asthma control.
• It facilitates reduction or cessation of oral corticosteroid therapy.
• This approach significantly decreases asthma exacerbations and healthcare utilization.